title: Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis.
abstract: BACKGROUND
  Inflammatory bowel diseases (IBD) are intestinal disorders characterized by inflammation in the gastrointestinal tract. Interleukin-10 is one of the most important anti-inflammatory cytokines involved in the intestinal immune system and because of its role in downregulating inflammatory cascades, its potential for IBD therapy is under study. We previously presented the development of an invasive strain of Lactococcus lactis (L. lactis) producing Fibronectin Binding Protein A (FnBPA) which was capable of delivering, directly to host cells, a eukaryotic DNA expression vector coding for IL-10 of Mus musculus (pValac:il-10) and diminish inflammation in a trinitrobenzene sulfonic acid (TNBS)-induced mouse model of intestinal inflammation. As a new therapeutic strategy against IBD, the aim of this work was to evaluate the therapeutic effect of two L. lactis strains (the same invasive strain evaluated previously and the wild-type strain) carrying the therapeutic pValac:il-10 plasmid in the prevention of inflammation in a dextran sodium sulphate (DSS)-induced mouse model.
  
  
  RESULTS
  Results obtained showed that not only delivery of the pValac:il-10 plasmid by the invasive strain L. lactis MG1363 FnBPA+, but also by the wild-type strain L. lactis MG1363, was effective at diminishing intestinal inflammation (lower inflammation scores and higher IL-10 levels in the intestinal tissues, accompanied by decrease of IL-6) in the DSS-induced IBD mouse model.
  
  
  CONCLUSIONS
  Administration of both L. lactis strains carrying the pValac:il-10 plasmid was effective at diminishing inflammation in this murine model of experimental colitis, showing their potential for therapeutic intervention of IBD.
authors.forename: Meritxell
authors.initials: M
authors.lastname: Zurita-Turk
authors.forename: Silvina
authors.initials: S
authors.lastname: Del Carmen
authors.forename: Ana C G
authors.initials: AC
authors.lastname: Santos
authors.forename: Vanessa B
authors.initials: VB
authors.lastname: Pereira
authors.forename: Denise C
authors.initials: DC
authors.lastname: Cara
authors.forename: Sophie Y
authors.initials: SY
authors.lastname: Leclercq
authors.forename: Alejandra dM
authors.initials: Ad
authors.lastname: de LeBlanc
authors.forename: Vasco
authors.initials: V
authors.lastname: Azevedo
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Chatel
authors.forename: Jean G
authors.initials: JG
authors.lastname: LeBlanc
authors.affiliation: Department of General Biology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil. miyoshi@icb.ufmg.br.
authors.forename: Anderson
authors.initials: A
authors.lastname: Miyoshi
mesh_terms: D000818:Animals; D003092:Colitis / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D016264:Dextran Sulfate / Q000633:toxicity; D004195:Disease Models, Animal; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism*; D007070:Immunoglobulin A / Q000378:metabolism; D007249:Inflammation / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D016753:Interleukin-10 / Q000235:genetics*; D015850:Interleukin-6 / Q000378:metabolism; D013294:Lactococcus lactis / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D012720:Severity of Illness Index; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
chemical_list: D007070:Immunoglobulin A; D015850:Interleukin-6; D016753:Interleukin-10; D014302:Trinitrobenzenesulfonic Acid; D016264:Dextran Sulfate
references.citation: Nat Rev Immunol. 2004 Jun;4(6):478-85
references.pmid: 15173836
references.citation: Inflamm Bowel Dis. 2009 Mar;15(3):341-52
references.pmid: 18942757
references.citation: Mol Pharm. 2011 Apr 4;8(2):488-97
references.pmid: 21271712
references.citation: Gastroenterology. 1997 Aug;113(2):383-9
references.pmid: 9247454
references.citation: Infect Immun. 2001 Oct;69(10):6296-302
references.pmid: 11553573
references.citation: Gastroenterology. 1990 Mar;98(3):694-702
references.pmid: 1688816
references.citation: J Bacteriol. 1993 Sep;175(18):5806-13
references.pmid: 8376328
references.citation: Gene Ther. 2008 Sep;15(17):1200-9
references.pmid: 18418416
references.citation: Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9
references.pmid: 16716759
references.citation: Orv Hetil. 2007 Feb 4;148(5):223-8
references.pmid: 17344143
references.citation: Gastroenterology. 1998 Jul;115(1):182-205
references.pmid: 9649475
references.citation: Am J Physiol Gastrointest Liver Physiol. 2000 Jul;279(1):G90-9
references.pmid: 10898750
references.citation: Appl Environ Microbiol. 2009 Jul;75(14):4870-8
references.pmid: 19482952
references.citation: Gut. 2001 Jul;49(1):42-6
references.pmid: 11413109
references.citation: Int Immunol. 1999 Sep;11(9):1573-80
references.pmid: 10464178
references.citation: Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G165-72
references.pmid: 16844678
references.citation: Genet Vaccines Ther. 2009 Feb 10;7:4
references.pmid: 19208231
references.citation: Cytokine Growth Factor Rev. 2004 Feb;15(1):61-76
references.pmid: 14746814
references.citation: Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):290-5
references.pmid: 21173247
references.citation: Cell. 1993 Oct 22;75(2):263-74
references.pmid: 8402911
references.citation: World J Gastroenterol. 2004 Mar 1;10(5):620-5
references.pmid: 14991925
references.citation: PLoS One. 2012;7(9):e44892
references.pmid: 23028664
references.citation: Nat Biotechnol. 2003 Jul;21(7):785-9
references.pmid: 12808464
references.citation: Gastroenterology. 2000 Dec;119(6):1461-72
references.pmid: 11113067
references.citation: Pharmacol Rev. 2003 Jun;55(2):241-69
references.pmid: 12773629
references.citation: Protein Expr Purif. 2011 Oct;79(2):165-75
references.pmid: 21704169
references.citation: ISRN Gastroenterol. 2011;2011:892971
references.pmid: 21991534